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ABSTRACT: Empyema is a serious complication of pneumonia and has been reported to have a mortality rate of 8.7%. For methicillin-resistant
Staphylococcus aureus (MRSA) empyema, treatment includes drainage and specific antibiotics such as vancomycin and linezolid. Strikingly,
there are increasing incidences of empyema refractory to vancomycin and linezolid. Despite being inactivated in the lung parenchyma by pulmonary surfactant, daptomycin can penetrate the pleural space and may be better at treating MRSA empyema than vancomycin and linezolid.
Some case reports have shown that daptomycin has been used to successfully treat MRSA empyema refractory to linezolid and vancomycinresistant enterococcus (VRE) empyema. Here, we present a 26-year-old male with a past medical history of intravenous (IV) drug use, newly
diagnosed HIV, HCV, and multifocal pneumonia complicated by a left-sided MRSA empyema that partially resolved with vancomycin and drainage. However, he subsequently developed a right-sided loculated pleural effusion. After the patient was switched to daptomycin with continued
drainage, the right and left pleural effusions improved significantly. Once medically stable, he was discharged to a rehabilitation facility for further
recovery. Our case report demonstrates that daptomycin could be considered as an effective treatment for MRSA empyema, particularly when
refractory to vancomycin.
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Introduction

and therefore is unable to treat pneumonia, its use for empyema
may preemptively be discarded.6,7 However, it is important to
remember that empyema forms within the pleural space, which
is outside of the lung parenchyma. Although surfactant molecules are present on pleural mesothelium, their composition
differs from that of pulmonary surfactant.8,9 Therefore, pulmonary surfactant is not present within the pleural space.
Moreover, no data could be found demonstrating that daptomycin is inactivated by pleural surfactant.
Furthermore, there have been 2 case reports suggesting that
vancomycin may not be as effective as once originally thought;
the reports demonstrated that daptomycin successfully treated
MRSA empyema refractory to linezolid and vancomycinresistant enterococci (VRE) empyema.10,11 Although these
reports are limited to a single patient, they suggest that daptomycin can treat MRSA empyema, particularly when unresponsive to standard antibiotics of choice including vancomycin and
linezolid. As of yet, there has been no evidence-based comparison between daptomycin and vancomycin in the treatment of
MRSA empyema. Here, we present a case of a 26-year-old
male presenting with multifocal pneumonia complicated by
left-sided MRSA empyema reduced to a small pleural effusion
on vancomycin. However, he subsequently developed a rightsided loculated pleural effusion that, alongside the left pleural
effusion, improved when switched to daptomycin.

Empyema is the accumulation of pus within the pleural space
and can be a serious complication of pneumonia, requiring
extensive treatment with antibiotics and adequate drainage.
Although the use of antibiotics has reduced the risk of empyema to 2% to 3% in patients with pneumonia, the incidence of
empyema is now rising.1 In the United States, the incidence of
empyema is as high as 10% in hospitalized patients with pneumonia, with a reported mortality rate of 8.7%.2,3 Additionally,
Staphylococcus aureus has been shown to be the most common
causative organism of pleural infections, including empyema,
and has been associated with increasing rates of drug resistance.4 Given the rise in cases of empyema, its significant mortality rate, and increasing drug resistance, treatment for
empyema is of particular importance.
In a patient hospitalized with community-acquired pneumonia complicated by empyema, the Infectious Diseases Society
of America guidelines recommend empiric treatment for
MRSA while waiting for cultures.5 Once MRSA is confirmed,
recommended antibiotic regimen includes 7 to 21 days of IV
vancomycin 600 mg twice per day, IV or oral linezolid 600 mg
twice per day, or IV or oral clindamycin 600 mg 3 times per day.
Strikingly, scarce literature exists on the use of daptomycin
to treat MRSA empyema. Since daptomycin is inactivated by
pulmonary surfactant lining the alveolar surface of the lungs
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Case Presentation

The patient was a 26-year-old male with a past medical history of IV drug use who was brought to the hospital by emergency medical services after being found obtunded at a train
station. Emergency medical technicians administered naloxone to reverse the effects of opioid-induced altered mental
status. On arrival at the emergency department, the patient’s
chief complaints were diffuse abdominal pain, dyspnea, and an
associated cough with an unknown time of onset. He stated
that, because of the distress caused by these symptoms, he
injected IV heroin. The patient was febrile (102°F), tachycardic (105-120 beats per minute), and tachypneic (18-30
breaths per minute) with an oxygen saturation ranging from
92% to 98% on room air. His laboratory results demonstrated
mild hyponatremia (sodium, 132 mEq/L) and elevated alanine
aminotransferase (ALT, 82 IU/L) and aspartate aminotransferase (AST, 67 IU/L), while his lipase, lactate, creatinine, and
glomerular filtration rate were within normal limits. White
blood cell (WBC) count was also normal at 7600 cells/µL. A
frontal chest x-ray demonstrated a moderate left-sided pleural
effusion, further evaluated by a chest CT scan without contrast illustrating multifocal pneumonia and a large fluid collection spanning half of the left hemithorax concerning for
empyema (Figures 1 and 2). Transthoracic echocardiogram
demonstrated no valvular vegetations. The patient underwent
diagnostic thoracentesis and left pleural chest tube placement.
Thoracentesis fluid demonstrated a pH of 6.84, elevated lactate dehydrogenase (LDH, 13 740 IU/L), and normal protein
(2.7 g/dL) consistent with empyema.
While awaiting pleural cultures, he was started on empiric
IV vancomycin 1500 mg (25 mg/kg, dosing weight of 60 kg)
every 8 hours and IV piperacillin/tazobactam 3.375 mg every
8 hours at 25 mL per hour. The target trough level for vancomycin was 15 to 20 µg/mL.
Pleural cultures returned positive for MRSA, which was
susceptible to vancomycin, clindamycin, and linezolid. Blood
cultures were negative. The patient was continued on vancomycin, and piperacillin/tazobactam was discontinued. Since
trough levels at the initial vancomycin dose and frequency were
subtherapeutic at 8-13 µg/mL, the dosage was adjusted to
1250 mg every 6 hours to achieve target trough levels. WBC
count remained within normal range throughout treatment
from 4900 cells/µL to 10 600 cells/µL.
Of note, during his hospital stay, the patient was newly
diagnosed with HIV (viral load of 673 000 copies/mL, CD4
count of 339 cells/MCL, genotype of HIV-1 subtype B) and
chronic HCV (viral load of 21 400 000 IU/mL). For HIV, he
was started on bictegravir, emtricitabine, and tenofovir alafenamide. Additionally, the patient’s hospital course was complicated by opioid withdrawal, for which he was given 30 mg of
methadone daily with 10 mg as needed for withdrawal symptoms per the clinical opiate withdrawal score (COWS).

Figure 1. Initial chest X-ray on admission demonstrating a moderate
left-sided pleural effusion.

Figure 2. Initial chest CT on admission demonstrating multifocal
pneumonia, healing fractures of the left fifth and sixth ribs, and a large
fluid collection covering approximately half of the left hemithorax with
concern for empyema.

Despite treatment with vancomycin at target trough levels,
the patient experienced persistent, intermittent fevers throughout his stay. There was initially an interval decrease in the size of
the left-sided empyema, resulting in chest tube removal after
1 week. However, repeat chest imaging including chest X-ray,
CT, ultrasound, and continued clinical symptoms demonstrated
that the patient had a persistent small, loculated pleural effusion
in the left lung base alongside the development of a new moderate-sized right-sided loculated pleural effusion with associated
right lower lobe atelectasis (Figure 3). Interventional radiologyguided thoracentesis of the right-sided pleural fluid revealed
murky and bloody fluid with a pH of 7.55, protein of 5.22 g/dL,
a cell count of 100 cells/µL with 69% neutrophils, and LDH of
850 IU/L. Subsequently, the patient underwent right chest tube
placement and drainage of pleural fluid was facilitated by multiple doses of TPA/Dornase, given the significant loculations in

Torjani et al

Figure 3. Chest CT within 1 week of treatment with IV vancomycin.
Compared to prior CT (Figure 2), the loculated left pleural effusion has
mostly resolved. There is a moderate enlarging right loculated pleural
effusion with adjacent worsening of atelectasis of the right lower lobe.

the effusion. Interestingly, right pleural cultures were negative,
although detectable bacterial growth may have been suppressed
with ongoing vancomycin treatment.
Given his inadequate improvement on vancomycin, the
patient was switched to IV daptomycin 300 mg (6 mg/kg per
day, dosing weight of 50 kg) daily for a total treatment duration
of 21 days. Having a similar spectrum of activity to linezolid
and clindamycin to which the isolated MRSA was found to be
susceptible, daptomycin was chosen for dosing convenience at
once per day. The patient’s intermittent fevers resolved after
the initiation of daptomycin. WBC count throughout treatment with daptomycin was within normal range from
3500 cells/µL to 6000 cells/µL. Prior to initiation of daptomycin, creatine kinase (CK) was 18 IU/L, which is below the normal range (25-215 IU/L) given his low muscle mass and a BMI
of 19 kg/m2. CK levels were measured after days 1 and 4 of
treatment at 19 IU/L and 16 IU/L, respectively.
Of note, 5 days after right chest tube placement, diminishing drainage amounts and repeat chest imaging demonstrated
that the chest tube was not appropriately placed with respect to
the remaining pleural fluid collection, requiring image-guided
replacement. After chest tube replacement and with continued
daptomycin treatment, the patient’s clinical symptoms began
to significantly improve. Chest CT without contrast after
6 days of daptomycin treatment demonstrated a decreased size
of the right loculated pleural effusion with a remaining small
left pleural effusion, allowing for right chest tube removal
(Figure 4). A midline was placed for the continuation of IV
daptomycin upon discharge and the patient was successfully
discharged to a rehabilitation facility shortly thereafter once
medically stable to complete the remaining antibiotic course.
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Figure 4. Chest CT after 6 days of daptomycin treatment. There is a
small loculated pleural effusion at the right basal region, decreased from
the prior study (Figure 3). The right chest tube is located distally within
the mid-upper portion of the right lung pleura wherein there is minimal
pleural fluid. There also remains a small stable left pleural effusion, as
well as a continued decrease in parenchymal consolidation and
atelectasis in the lower lobes.

Per the discharge recommendations of the infectious disease
team, C-reactive protein and CK levels were monitored weekly
while on treatment, resulting within normal limits. Although
the patient was contacted for his outpatient appointment, he
was unreachable and lost to follow-up.

Discussion

Multiple sources have demonstrated that daptomycin is effective in treating MRSA for various infections.12,13 However,
daptomycin is scarcely used to treat respiratory infections
because of its limited efficacy in the lung parenchyma. In this
case report, we reiterate the importance of distinguishing
between the lung parenchyma and pleural space to ensure an
optimized treatment, especially in a potentially life-threatening
situation such as our immunocompromised patient with multifocal pneumonia complicated by MRSA empyema.
Daptomycin is a desirable option for treating empyema due
to its potentially stronger penetration into the pleural space
compared to vancomycin; this may improve the recovery rate
and reduce the risk of complications such as a loculated pleural
effusion as seen in our patient.10 However, this finding stemmed
from a case report within the setting of VRE empyema, which
limits its generalizability. Additionally, daptomycin can be
more conveniently dosed at once daily, while vancomycin
requires more frequent dosing at twice daily and serial measurements of trough levels.5 Although daptomycin necessitates
monitoring for myopathy via routine measurements of CK, its
simple dose regimen eases administration and may improve
patient compliance.14 Despite these benefits of daptomycin,
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more research is needed to quantify and compare the efficacy of
antibiotics that can treat MRSA pleural infections, including
daptomycin, vancomycin, and linezolid.
It is also important to consider the context in which daptomycin is used to treat MRSA empyema. Since it is inactivated
in the lungs, daptomycin can only treat empyema in the setting
of nonexistent or resolved pneumonia. Given that many cases of
empyema arise in the setting of ongoing pneumonia, daptomycin may need to be used in adjunct with another antibiotic.
Conversely, vancomycin could concurrently treat both pneumonia and empyema. However, a growing number of case reports
have suggested that empyema can be refractory to vancomycin.10,11 Our case report also found a concomitant pleural complication despite vancomycin treatment. Therefore, in the
setting of ongoing MRSA pneumonia and empyema, one could
consider using vancomycin to treat pneumonia and transition to
daptomycin to treat empyema. This combination ensures adequate treatment of pneumonia and provides enhanced treatment for empyema. Further studies are needed to compare the
use of combined vancomycin and daptomycin to vancomycin
alone in the setting of pneumonia complicated by empyema.
While this case report reaffirms the findings of previous
reports on daptomycin effectively treating empyema, it is limited to a single patient whose medical history, including IV
drug use, HCV, and HIV, may not reflect the clinical course for
all patients who have MRSA empyema. The right pleural effusion may have been due to the patient’s immunocompromised
state rather than to a drug limitation. Additionally, the right
pleural effusion may have resolved as a result of correcting the
chest tube placement. Nonetheless, our patient had no further
complications and continued to improve after switching to
daptomycin. This suggests that daptomycin can effectively
treat MRSA empyema, particularly if unresponsive to
vancomycin.

Conclusion

Although previous case reports have suggested that daptomycin
can treat empyema, we believe that this is the first case report to
demonstrate the successful treatment with daptomycin of
MRSA empyema refractory to vancomycin. Our case report
reiterates the importance of considering alternative medications
in MRSA empyema that persists with sequelae of complications despite mainstay antibiotic treatment and drainage.
Daptomycin’s convenient dosing and potential to better penetrate the pleural space could not only optimize treatment efficacy and duration, but also hold the potential to reduce the risk
of further complications and mortality. Therefore, daptomycin
could be more strongly considered as a treatment option for
MRSA empyema, especially when unresponsive to standard
antibiotics of choice such as vancomycin.
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